Ten-year experience of bone SBRT in breast cancer: analysis of predictive factors of effectiveness

• Héctor Pérez-Montero ^[1] ; Alicia Lozano ^[1] ; Rodolfo de Blas ^[1] ; Juan José Sánchez ^[2] ; Evelyn Martínez ^[1] ; María Laplana ^[1] ; Miguel Gil-Gil ^[1] ; Amparo Garcia-Tejedor ^[2] ; Sonia Pernas ^[1] ; Catalina Falo ^[1] ; Óscar Godino ^[2] ; MariaJ. Pla ^[2] ; Ferrán Guedea ^[1] ; Arturo Navarro-Martin ^[1]
  1. [1] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  2. [2] Hospital Universitari de Bellvitge

     Hospital Universitari de Bellvitge

     l'Hospitalet de Llobregat, España

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 6, 2023, págs. 1756-1766
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Data on the benefit of stereotactic body radiation therapy (SBRT) in patients with breast cancer (BC) and bone metastases remain limited. The purpose of this study is to report our 10-year experience of bone SBRT, analyzing toxicity and prognostic factors for local control (LC); progression-free survival, and overall survival (OS).

    Methods/patients We analyzed all spine and non-spine bone SBRT performed in patients with BC during the 2012–2022 period at our institution. Treatments carried out with ablative intent in stereotactic conditions with dose/fraction ≥ 5 Gy in 5 or fewer sessions were considered. Demographic, treatment, and toxicity data were recorded according to CTCAEv4. Risk factors were assessed through univariate and multivariate analysis by Cox regression.

    Results 60 bone SBRT treatments were performed during the study period. 75% were spine SBRT and 25% were non-spine SBRT (median BED4Gy was 80 Gy4). The median age was 52.5 years (34–79). The median tumor volume was 2.9 cm3 (0.5–39.4). The median follow-up was 32.4 months (1.2–101.7). 1 and 2 years LC were 92.9 and 86.6%, respectively. 1 and 2 years OS were 100 and 90.6%, respectively. Multivariate analysis (MVA) associated volume of the treated lesion ≥ 13 cm3 with worse LC (p = 0.046; HR 12.1, 95%CI = 1.1–140.3). In addition, deferring SBRT > 3 months after lesion diagnosis to prioritize systemic treatment showed a significant benefit, improving the 2 years LC up to 96.8% vs. 67.5% for SBRT performed before this period (p = 0.031; HR 0.1, 95%CI = 0.01–0.8). Hormonal receptors, the total number of metastases, and CA15-3 value were significantly associated with OS in MVA. During follow-up, three non-spine fractures (5%) were observed.

    Conclusions According to our data, bone SBRT is a safe and effective technique for BC. Upfront systemic treatment before SBRT offers a benefit in LC. Therefore, SBRT should be considered after prior systemic treatment in this population.